HAS2 and neoplasm: Our results indicate that reduced immunopositivity of HAS2 is associated with several known unfavorable histopathologic prognostic markers like a reduced number of tumor infiltrating lymphocytes (TIL), an increased melanoma horizontal diameter, an increased mitotic activity and the nodular subtype.